Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from 89bio

Akero Therapeutics Stock Nearly Doubles — Pulling 89bio Higher — On Positive MASH Study

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH obliterated expectations.

Investors Business Daily

Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH

Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH

Madrigal stock plummeted Wednesday on detailed results from a study of Eli Lilly's weight-loss drug in patients with a serious liver disease.

Investors Business Daily

Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment

Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment

Biotech stocks Akero Therapeutics and 89bio rocketed Monday after the former announced promising test results for a liver disease treatment.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Weight-Loss Tizzy: Why Altimmune Surged 23% As Others Tumbled On A New Study

Biotech stocks Madrigal and Altimmune diverged Monday as Wall Street debated the outcome of a weight-loss study in MASH patients.

Investors Business Daily

Why Akero Therapeutics Lost More Than Half Its Value And Dragged Down 89bio

Shares of Akero Therapeutics and 89bio stock crashed Tuesday after Akero's treatment for the liver disease, NASH, fell short in a midstage study.

Investors Business Daily

Top 1% Biotech 89bio Scores 25% Gain As Battle In Liver Disease Heats Up

Small biotech company 89bio scored a win Wednesday in fatty liver disease, and ETNB stock rocketed well above its 50-day moving average.

Investors Business Daily

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

inkl

Read news from The Economist, FT, and more,
with one subscription

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17,…

5 Analysts Have This to Say About 89bio

5 Analysts Have This to Say About 89bio

Over the past 3 months, 5 analysts have published their opinion on 89bio (NASDAQ:ETNB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

89bio Posts Promising Pegozafermin Data For Severe Hypertriglyceridemia

89bio Posts Promising Pegozafermin Data For Severe Hypertriglyceridemia

89bio Inc (NASDAQ: ETNB)

89bio Pulls Back With Market — But Could The Stock Soar 250%?

89bio Pulls Back With Market — But Could The Stock Soar 250%?

89bio, Inc (NASDAQ: ETNB) was plunging almost 10% lower on Friday in sympathy with the general market, which saw the S&P 500 plummeting over 2%.

Analyst Ratings for 89bio

Analyst Ratings for 89bio

89bio (NASDAQ:ETNB) has observed the following analyst ratings within the last quarter:

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Intraday Session

Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2022

Get all your
news in one place.

100’s of premium titles.
One news app.

Recap: 89bio Q1 Earnings

89bio (NASDAQ:ETNB) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings 89bio beat estimated earnings by 2.33%, reporting an EPS of $-1.26 versus an estimate of $-1.29.

89bio's NASH Candidate Shows Improvement In Disease Severity, Cardiovascular Health

89bio Inc (NASDAQ: ETNB)

Organisations

American Express

ON Semiconductor

Rivian Automotive

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

108,040 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play